Mirco Ponzoni

Dr. Mirco Ponzoni

orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in The American Journal of Pathology
Verified
Journal Article
Closed access
MBMonica Bacci
Monica Bacci
ACAnnalisa Capobianco
Annalisa Capobianco
AMAntonella Monno
Antonella Monno
LCLucia Cottone
Lucia Cottone
FPFrancesca Di Puppo
Francesca Di Puppo
PRPatrizia Rovere-Querini
Patrizia Rovere-Querini

15 October 2006 in Cancer Research
Verified
Journal Article
Open access
PDF file
Fabio PastorinoFabio Pastorino
Fabio Pastorino
CBChiara Brignole
Chiara Brignole
DPDaniela Di Paolo
Daniela Di Paolo
BNBice Nico
Bice Nico
APAnnalisa Pezzolo
Annalisa Pezzolo
MPMirco Ponzoni
Mirco Ponzoni
Neuroblastoma, the most common solid tumor of infancy derived from the sympathetic nervous system, continues to present a formidable clinical challenge. Sterically stabilized immunoliposomes (SIL) have been shown to enhance the selective localization of entrapped drugs to solid tumors, with improvements in therapeutic indices. We showed that SIL loaded with doxorubicin (DXR) and targeted to the disialoganglioside receptor GD2 [aGD2-SIL(DXR)] led to a selective inhibition of the metastatic growth of experimental models of human neuroblastoma. By coupling NGR peptides that target the angiogenic endothelial cell marker aminopeptidase N to the surface of DXR-loaded liposomes [NGR-SL(DXR)], we obtained tumor regression, pronounced destruction of the tumor vasculature, and prolonged survival of orthotopic neuroblastoma xenografts. Here, we showed good liposome stability, long circulation times, and enhanced time-dependent tumor accumulation of both the carrier and the drug. Antivascular effects against animal models of lung and ovarian cancer were shown for formulations of NGR-SL(DXR). In the chick embryo chorioallantoic assay, NGR-SL(DXR) substantially reduced the angiogenic potential of various neuroblastoma xenografts, with synergistic inhibition observed for the combination of NGR-SL(DXR) with aGD2-SIL(DXR). A significant improvement in antitumor effects was seen in neuroblastoma-bearing animal models when treated with the combined formulations compared with control mice or mice treated with either tumor- or vascular-targeted liposomal formulations, administered separately. The combined treatment resulted in a dramatic inhibition of tumor endothelial cell density. Long-term survivors were obtained only in animals treated with the combined tumor- and vascular-targeted formulations, confirming the pivotal role of combination therapies in treating aggressive metastatic neuroblastoma. (Cancer Res 2006; 66(20): 10073-82)

15 April 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MSMichaela Semeraro
Michaela Semeraro
SRSylvie Rusakiewicz
Sylvie Rusakiewicz
VMVéronique Minard-Colin
Véronique Minard-Colin
NDNicolas F. Delahaye
Nicolas F. Delahaye
DEDavid Enot
David Enot
LZLaurence Zitvogel
Laurence Zitvogel
The immunosurveillance mechanisms governing high-risk neuroblastoma (HR-NB), a major pediatric malignancy, have been elusive. We identify a potential role for natural killer (NK) cells, in particular the interaction between the NK receptor NKp30 and its ligand, B7-H6, in the metastatic progression and survival of HR-NB after myeloablative multimodal chemotherapy and stem cell transplantation. NB cells expressing the NKp30 ligand B7-H6 stimulated NK cells in an NKp30-dependent manner. Serum concentration of soluble B7-H6 correlated with the down-regulation of NKp30, bone marrow metastases, and chemoresistance, and soluble B7-H6 contained in the serum of HR-NB patients inhibited NK cell functions in vitro. The expression of distinct NKp30 isoforms affecting the polarization of NK cell functions correlated with 10-year event-free survival in three independent cohorts of HR-NB in remission from metastases after induction chemotherapy (n = 196, P < 0.001), adding prognostic value to known risk factors such as N-Myc amplification and age >18 months. We conclude that the interaction between NKp30 and B7-H6 may contribute to the fate of NB patients and that both the expression of NKp30 isoforms on circulating NK cells and the concentration of soluble B7-H6 in the serum may be clinically useful as biomarkers for risk stratification.

25 February 2002 in Cell Death & Differentiation
Verified
Journal Article
Closed access
ICI Casciano
I Casciano
KMkatia mazzocco
katia mazzocco
LBL Boni
L Boni
GPG Pagnan
G Pagnan
BBBarbara Banelli
Barbara Banelli
MRM Romani
M Romani

Verified
Journal Article
Open access
PDF file
MPMirco Ponzoni
Mirco Ponzoni
Fabio PastorinoFabio Pastorino
Fabio Pastorino
DPDaniela Di Paolo
Daniela Di Paolo
PPPatrizia Perri
Patrizia Perri
CBChiara Brignole
Chiara Brignole
Macrophages, cells belonging to the innate immune system, present a high plasticity grade, being able to change their phenotype in response to environmental stimuli. They play central roles during development, homeostatic tissue processes, tissue repair, and immunity. Furthermore, it is recognized that macrophages are involved in chronic inflammation and that they play central roles in inflammatory diseases and cancer. Due to their large involvement in the pathogenesis of several types of human diseases, macrophages are considered to be relevant therapeutic targets. Nanotechnology-based systems have attracted a lot of attention in this field, gaining a pivotal role as useful moieties to target macrophages in diseased tissues. Among the different approaches that can target macrophages, the most radical is represented by their depletion, commonly obtained by means of clodronate-containing liposomal formulations and/or depleting antibodies. These strategies have produced encouraging results in experimental mouse models. In this review, we focus on macrophage targeting, based on the results so far obtained in preclinical models of inflammatory diseases and cancer. Pros and cons of these therapeutic interventions will be highlighted.

16 August 2006 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
CBChiara Brignole
Chiara Brignole
DMDanilo Marimpietri
Danilo Marimpietri
Fabio PastorinoFabio Pastorino
Fabio Pastorino
BNBeatrice Nico
Beatrice Nico
DPDaniela Di Paolo
Daniela Di Paolo
MPMirco Ponzoni
Mirco Ponzoni
Background: Bortezomib is a selective and reversible inhibitor of the 26S proteasome that shows potent antitumor activity in vitro and in vivo against several human cancers of adulthood. No data are available on bortezomib activity against human pediatric neuroblastoma. Methods: Ten neuroblastoma cell lines and suspensions of primary neuroblastoma cells from three patients were tested for sensitivity to bortezomib. Colony formation, cell proliferation, cell cycle progression, and apoptosis were evaluated by a clonogenic assay and by measuring 3 H-thymidine incorporation, bromodeoxyuridine uptake, DNA fragmentation, and phosphatidylserine exposure and propidium iodide staining, respectively. Angiogenesis was assessed by the chick embryo chorioallantoic membrane (CAM) assay. Two mouse xenograft models that mimic the growth and spread of neuroblastoma in humans were used to examine in vivo sensitivity of neuroblastoma to bortezomib. All statistical tests were two-sided. Results: Bortezomib inhibited proliferation and colony formation of neuroblastoma cell lines in a time- and dose-dependent manner. The mean bortezomib concentration that caused 50% inhibition of growth was 6.1 nM (95% confidence interval [CI] = 0.9 to 11.3 nM) at 72 hours. Bortezomib-treated neuroblastoma cells were arrested at G 2 /M and underwent apoptosis (mean percentage of apoptotic cells in four neuroblastoma cell lines treated with 20 nM bortezomib for 24 hours ranged from 20% to 35%, and caspases were activated by two- to fivefold with respect to untreated cells). Similar results were obtained for primary neuroblastoma cells exposed to bortezomib. Bortezomib inhibited angiogenesis in CAMs stimulated by conditioned medium from neuroblastoma cell lines, by neuroblastoma xenografts, and by primary neuroblastoma biopsy specimens (microvessel area: 2.9 × 10 −2 mm 2 , 95% CI = 1.8 × 10 −2 to 3.8 × 10 −2 mm 2 in CAMs treated with biopsy specimens alone and 1.3 × 10 −2 mm 2 , 95% CI = 1 × 10 −2 to 1.5 × 10 −2 mm 2 in CAMs treated with biopsy specimens plus bortezomib, P = .024). In both mouse models, mice treated with bortezomib lived statistically significantly longer than control mice (mean survival time in the pseudometastatic model: 74.2 versus 50.3 days, P <.001; mean survival time in the orthotopic model: 72.3 versus 50.6 days, P <.001). Conclusions: Bortezomib is an effective inhibitor of neuroblastoma cell growth and angiogenesis. These findings provide the rationale for further clinical investigation of bortezomib in pediatric neuroblastoma.